Semaglutide
vs Retatrutide.
Compare semaglutide and retatrutide by approved versus investigational status, GLP-1 and triple-agonist mechanisms, trial results, and evidence limits.
What is the difference?
Semaglutide and retatrutide have not been compared in a randomized head-to-head trial. Semaglutide is a GLP-1 receptor agonist used in several product-specific approved medicines, including WEGOVY under FDA application NDA 215256. Retatrutide is Lilly's investigational once-weekly GIP, GLP-1, and glucagon receptor triple agonist and is not FDA approved. WEGOVY and STEP evidence and retatrutide's 80-week TRIUMPH-1 result come from separate programs, populations, doses, durations, comparators, and statistical analyses. Those results can explain each evidence record, but they cannot prove that retatrutide is better, safer, more durable, or appropriate for an individual.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Semaglutide
FDA-approved prescription drug
- Route
- Subcutaneous and oral
- Registry
- Dedicated medicine evidence record
- Sponsor
- Novo Nordisk Inc.
Retatrutide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 34 matched NCT records
- Sponsor
- Eli Lilly and Company
Semaglutide vs Retatrutide: how direct is the evidence?
No participant in the cited sources was randomized between Semaglutide and Retatrutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Semaglutide
GLP-1 receptor agonist
- Route
- Subcutaneous and oral
- Stage
- NDA 215256 approved product record
- Status
- FDA-approved prescription drug
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialRetatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
Outside this 13-program snapshot
This comparison uses an approved-medicine record here. A blank is a scope boundary, not evidence that no clinical trial or trial history exists.
Open the bounded clinical trial finder →matched NCT records
- Recruiting
- 2
- Results posted
- 2
- Recruiting site observations
- 450
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Semaglutide
GLP-1 receptor agonist
- Route
- Subcutaneous and oral
- Stage
- NDA 215256 approved product record
- Status
- FDA-approved prescription drug
- Featured trial anchors
- NDA 215256
Retatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT05929066 · NCT05931367 · NCT05882045
Compare the field, then read the limit.
This comparison combines an approved ingredient with an investigational Phase 3 program and asks which one causes more weight loss. The honest answer must first resolve semaglutide to an exact product, label, presentation, and country, then preserve retatrutide's investigational status. Receptor count and the largest separate-trial percentage do not replace randomized comparative evidence, regulatory review, long-term safety, adherence, coverage, or individual clinical judgment.
| Field | Semaglutide | Retatrutide | How to interpret it |
|---|---|---|---|
| Mechanism | GLP-1 receptor agonist | GIP, GLP-1, and glucagon receptor triple agonist | Retatrutide adds two receptor activities, but receptor count alone does not establish comparative benefit, risk, or tolerability. |
| Current status | Semaglutide has product-specific approvals, including WEGOVY NDA 215256 | Investigational Phase 3 program with no FDA-approved product | An approved ingredient record and an investigational development program occupy different regulatory and access categories. |
| Evidence anchor | WEGOVY label and semaglutide trial records tied to exact products and protocols | 28.3% at 80 weeks in TRIUMPH-1 under an efficacy estimand | The sources answer different clinical questions and cannot be combined into a randomized comparative effect estimate. |
| Direct comparison | No randomized arm against retatrutide | No randomized arm against semaglutide | Without a common protocol, superiority, noninferiority, relative safety, adherence, and preference remain unresolved. |
| Product identity | Ingredient name spans separate brands, applications, forms, and country records | Development name identifies an unapproved Lilly clinical program | Neither name authenticates a compounded product, research vial, imported presentation, seller, or local supply claim. |
Why the headline numbers do not name a winner.
Retatrutide's 28.3% figure came from the 12 mg TRIUMPH-1 group at 80 weeks under an efficacy estimand in adults with obesity or overweight without diabetes. Semaglutide results commonly cited from WEGOVY and STEP records use different protocols, treatment periods, eligibility rules, products, and analysis plans. No participant was randomized between semaglutide and retatrutide in the sources cited here. Subtracting percentages, dividing them into weekly rates, or treating one product label as the complete ingredient record would create a comparison the evidence does not support.
Keep the comparison honest.
- 01
Resolve semaglutide claims to an exact brand, application, presentation, indication, jurisdiction, dose, and trial before comparing any percentage.
- 02
Do not compare a semaglutide result with TRIUMPH-1 as though the studies shared randomization, duration, population, comparator, dose plan, or estimand.
- 03
Treat retatrutide as investigational and separate online availability claims from sponsor trials, FDA approval, pharmacy access, and authentic product identity.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →